Shareholder Vote

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2017 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 7327 Oak Ridge Hwy., Knoxville, Tennessee 37931 (Address of Principal Executive Offices) (866) 594-5999 (Registrant’s Telephone Number, Including Area Code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.07. Submission of Matters to a Vote of Security Holders. (a) Provectus Biopharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders on Tuesday, May 30, 2017. (b) At the 2017 annual meeting, the Company’s stockholders voted on six proposals. A brief description and tabulation of votes for each proposal are set forth below. Proposal 1 . The Company’s stockholders elected the following directors for a term of one year, consistent with the recommendation of the Company’s Board of Directors (the “Board”). There were 155,379,803 broker non-votes with respect to the proposal. Nominee For Withheld Bruce Horowitz 114,749,847 12,563,928 Jan E. Koe 113,862,809 13,450,966 Dominic Rodrigues 116,728,417 10,585,358 Eric A. Wachter, Ph.D. 111,570,360 15,743,415 Proposal 2 . The Company’s stockholders approved the advisory vote on the compensation of the Company’s named executive officers, consistent with the Board’s recommendation. There were 155,379,803 broker non-votes with respect to the proposal. For Against Abstain 108,049,907 17,665,031 1,598,837 Proposal 3 . The Company’s stockholders expressed their preference to conduct future advisory votes on executive compensation every year, consistent with the Board’s recommendation. There were 155,379,803 broker non-votes with respect to the proposal. This policy will remain in effect until the next advisory stockholder vote as would be set forth in the Company’s proxy statement for its 2023 annual meeting. One Year Two Years Three Years Abstain 116,841,564 3,721,040 4,789,375 1,961,796 Proposal 4 . The Company’s stockholders ratified the selection of Marcum LLP as the Company’s independent registered public accounting firm for 2017, consistent with the Board’s recommendation. There were no broker non-votes with respect to the proposal. For Against Abstain 262,554,263 15,704,221 4,435,094 Proposal 5 . The Company’s stockholders did not approve an amendment of the Certificate of Incorporation, as amended, to increase the number of authorized shares of preferred stock, as a majority of the outstanding shares of common stock entitled to vote were required to vote in favor of this proposal in order to approve it. There were 155,379,803 broker non-votes with respect to the proposal. For Against Abstain 102,632,187 23,924,913 756,675 Proposal 6 . The Company’s stockholders approved an amendment of the Provectus 2014 Equity Compensation Plan to allow for the grant of restricted stock awards, consistent with the Board’s recommendation. There were 155,379,803 broker non-votes with respect to the proposal. For Against Abstain 103,063,213 17,488,420 6,762,142 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 1, 2017 PROVECTUS BIOPHARMACEUTICALS, INC. By: /s/ Timothy C. Scott Timothy C. Scott President